Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report

• Главные авторы: Kazumi Nishino (Автор), Kei Kunimasa (Автор), Madoka Kimura (Автор), Takako Inoue (Автор), Motohiro Tamiya (Автор), Hanako Kuhara (Автор), Toru Kumagai (Автор)
• Формат: ‌
• Опубликовано: BMC, 2020-04-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Background Pulmonary sarcomatoid carcinoma is a rare non-small-cell lung cancer (NSCLC) subtype with a poor prognosis. In the phase III PACIFIC study, durvalumab significantly improved progression-free survival and overall survival versus placebo, in patients with stage III NSCLC who do not...